Epilepsy: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• NMDA 0
• mTOR 3
• SCN1A 6
• SCN2A 2
• HMGB1 0
• PPAR 0
• BDNF 1
• NLRP3 0
• TLR4 0
• NRF2 0
• PTEN 0
• AKT 0
• PI3K 0
• IDH 0
• GLP-1 0
• IL-1 1
• JAK 0
• GPX4 0
• AMPK 0
• CTNNB1 1
• MAPK 0
• APOE 0
• COX-2 0
• SGLT2 0
• SIRT1 0
• STING 0
• TNF 0
• ERK 1
• HIF-1 0
• STAT3 0
• TP53 0
• TREM2 0
• CGRP 0
• HDAC 0
• MAPT 0
• YAP 0
• APP 0
• CXCR4 0
• HSP90 0
• IL-6 0
• JNK 0
• MDM2 0
• NOTCH1 0
• NOTCH3 0
• PD-1 0
• PINK1 0
• AQP4 0
• AR 0
• B7-H3 0
• BACE1 0
• BCL-2 0
• BRAF 0
• BRD4 0
• CD47 0
• DMD 0
• DPP-4 0
• FGFR 0
• FTO 0
• G6PD 0
• GBA1 0

8 of 8+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIMH · F30

  Neural Correlates of Memory-Based Generalization in Humans

  University of California at Davis· Davis, United States· US$43,749 awarded in fiscal year 2026· until Sept 2030

• ALLCDC NCCDPHP · U01

  Epilepsy Incidence Among Children in the United States

  National Opinion Research Center· Chicago, United States· US$443,851 awarded in fiscal year 2025· until Sept 2030

• ALLCDC NCCDPHP · U01

  Advancing Understanding of Pediatric Epilepsy Incidence and Risk Factors: A Multilevel Population Health Approach

  Massachusetts General Hospital· Boston, United States· US$418,550 awarded in fiscal year 2025· until Sept 2030

• NIH NINDS · F31

  Slow-Wave Sleep Enhancement to Treat Epilepsy

  University of California at Davis· Davis, United States· US$43,749 awarded in fiscal year 2026· until Sept 2029

• ALLCDC NCCDPHP · U01

  Incidence and Risk Factors of Childhood Epilepsy in the United States

  Case Western Reserve University· Cleveland, United States· US$499,995 awarded in fiscal year 2025· until Sept 2030

• European Commission (Horizon Europe) · HORIZON-ERC

  From single neuron to brain: multi-level strategy and digital twins for personalized prediction of treatment (Neuron2Brain)

  Universita Degli Studi di Genova· Genova, Italy· EU contribution €1,500,000· until Feb 2032

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unravelling the Role of Cerebral Amyloid-beta Angiopathy in Epilepsy: Inflammatory Pathways and Interneuron Dysfunction (EPICAA)

  Ludwig-Maximilians-Universitaet Muenchen· Planegg, Germany· EU contribution €217,965· until Feb 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  The role of subcortical structures in perceptual consciousness: a causal investigation (StimConscious)

  Katholieke Universiteit Leuven· Leuven, Belgium· EU contribution €424,129· until Jan 2030· 3 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Standardized patient‑friendly computational language mapping to guide epilepsy surgery (SPEEDY-Clinic)

  Institut National de la Sante Et de la Recherche Medicale· Paris, France· EU contribution €150,000· until Jun 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  High-throughput screen for disfunctions in GABA-switch in human neuronal models of SNAREopathies

  Kobenhavns Universitet· Kobenhavn, Denmark· EU contribution €247,553· until Oct 2028

  The disease is named only in the funder's project summary, not in the title.

10 of 1,283 running projects, newest first. Listed amounts together: US$626.6m + €184.0m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 8
• Organoids 13
• Mendelian Randomization Analysis 36
• CRISPR-Cas Systems 9
• Gene Expression Profiling 28
• Sequence Analysis, RNA 4
• Whole Genome Sequencing 14
• Exome Sequencing 114
• Proteomics 23
• Metabolomics 23
• Mass Spectrometry 7
• Flow Cytometry 3
• Immunohistochemistry 21
• Liquid Biopsy 1
• Xenograft Model Antitumor Assays 2
• Positron-Emission Tomography 70
• Magnetic Resonance Imaging 573
• Machine Learning 112
• Deep Learning 78
• Cohort Studies 313
• Genome-Wide Association Study 37

• Development of a human iPSC and patient phenotyping resource for preclinical investigations of neurodevelopmental disorders.

  Stem Cell Res, Aug 2026

• Generation of a FRMD5 knockout human embryonic stem cell line by CRISPR/Cas9 editing.

  Stem Cell Res, Jun 2026

• CRISPR-Based Gene Therapy for Brain Disease.

  Mol Neurobiol, Jun 2026

• Gene Editing Strategies for Neurological and Mental Disorders: Advances in Delivery, Methodology, and Clinical Translation.

  Cells, Apr 2026

• Targeted Gene and Genome-Editing Strategies for Epilepsy: Experimental Advances and Translational Challenges.

  Int J Mol Sci, Mar 2026

• Isogenic modeling of 1q21.1 reciprocal CNVs in human ES cells reveals divergent neurodevelopmental trajectories.

  Hum Mol Genet, Feb 2026

• Generation of a SV2A knockout human embryonic stem cell line by CRISPR/Cas9 system.

  Stem Cell Res, Feb 2026

• Engineering a human-based translational activator for targeted protein expression restoration.

  Nucleic Acids Res, Feb 2026

• A hit for base editing: treatment of developmental epilepsy in a mouse model.

  J Clin Invest, Feb 2026

See which targets of this disease your abstract mentions, and go to the people working on them.